Duloxetine Capsule, Delayed Release
Product Images NDC 50090-6281

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Duloxetine (NDC 50090-6281). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Structure (C5b0f981 45c3 4e15 B712 984b4a4f6a57 01)

Chemical structure diagram of duloxetine hydrochloride displaying its molecular framework, including a naphthyl group, thiophene ring, and methylated amine with hydrochloride salt form.*

FDA Label Image

Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 02)

A Kaplan-Meier survival plot showing the proportion of patients with relapse over time (days) from randomization comparing placebo with Duloxetine treatment. The graph demonstrates relapse rates on the y-axis from 0 to 1 and time on the x-axis up to about 200 days, with placebo showing a higher relapse proportion than Duloxetine.*

FDA Label Image

Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 03)

A Kaplan-Meier estimator graph showing the proportion of patients with relapse over time (days) from randomization. The graph compares two treatments: Duloxetine (solid line) and placebo (dashed line), illustrating relapse rates over approximately 250 days.*

FDA Label Image

Figure 1 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 04)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline. It compares Duloxetine at 60 mg twice daily, 60 mg once daily, 20 mg once daily, and placebo, illustrating variations in patient improvement across different dosages and placebo groups.*

FDA Label Image

Figure 2 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 05)

A line chart depicting the percentage of patients improved versus percent improvement in pain from baseline. It compares three groups: Duloxetine 60 mg BID, Duloxetine 60 mg QD, and Placebo. The y-axis shows the percentage of patients improved, while the x-axis shows percent improvement in pain, ranging from 0 to 100.*

FDA Label Image

Fig 5 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 06)

A line chart comparing the percentage of patients improved against percent improvement in pain from baseline for three groups: Duloxetine 60 mg twice daily, Duloxetine 60 mg once daily, and placebo. The chart shows higher patient improvement percentages for both Duloxetine groups compared to placebo across increasing pain improvement percentages.*

FDA Label Image

Fig 6 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 07)

A line graph showing the percentage of patients improved versus percent improvement in pain from baseline for Duloxetine at various doses and placebo. Four lines represent Duloxetine 120 mg twice daily, Duloxetine 60 mg once daily (two data series), and placebo, illustrating patient response rates across different pain improvement thresholds.*

FDA Label Image

Figure 8 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 08)

A line graph comparing the percentage of patients improved between placebo and Duloxetine 60/120 mg once daily across various levels of percent improvement in pain from baseline (BOCF). The x-axis represents percent improvement in pain from greater than 0 to 100, and the y-axis shows the percentage of patients improved from 0 to 100%. Two lines display trends for placebo and Duloxetine, with Duloxetine consistently showing higher patient improvement percentages compared to placebo.*

FDA Label Image

Figure 9 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 09)

A line graph comparing percentage of patients improved versus percent improvement in pain from baseline (BOCF) for Duloxetine 60 mg once daily and placebo groups. The x-axis shows percent improvement in pain from baseline ranging from greater than 0 to 100, while the y-axis shows percentage of patients improved from 0 to 100. Duloxetine treatment shows generally higher percentages of patient improvement across the pain improvement spectrum.*

FDA Label Image

Figure 10 (C5b0f981 45c3 4e15 B712 984b4a4f6a57 10)

A line graph depicting the percentage of patients improved based on the percent improvement in pain from baseline (BOCF). The graph compares Duloxetine 60/120 mg once daily versus placebo, showing a higher percentage of patient improvement across various pain improvement thresholds for Duloxetine compared to placebo.*

FDA Label Image

Label Image (Lbl500906281)

Label for Duloxetine 30 mg delayed-release capsules by A-S Medication Solutions. The label displays the NDC 50090-6281-0 and indicates the package contains 30 capsules. It includes storage instructions to store at 77 degrees Fahrenheit and dosage packaging information with a unique package insert number.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.